This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
CRL Stock to Gain From Strategic Neuroscience Partnership With CEBINA
by Zacks Equity Research
Charles River collaborates with CEBINA as part of the DanubeNeuro program to advance innovation in neurodegeneration.
CRL Stock May Benefit From New Neuroscience Research Collaboration
by Zacks Equity Research
Charles River's new alliance with Insightec to advance therapeutic development using focused ultrasound in neuroscience.
Why Is Charles River (CRL) Down 5.3% Since Last Earnings Report?
by Zacks Equity Research
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Charles River (CRL) International Revenue Trends Deserve Your Attention
by Zacks Equity Research
Examine Charles River's (CRL) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Charles River (CRL) Q2 Earnings Beat Estimates, 2024 View Down
by Zacks Equity Research
Charles River's (CRL) Manufacturing business segments report organic revenue growth, partially offset by lower revenues in the DSA and RMS segments.
Here's What Key Metrics Tell Us About Charles River (CRL) Q2 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Charles River (CRL) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Charles River Laboratories (CRL) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 17.15% and 0.09%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Unlocking Q2 Potential of Charles River (CRL): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Here's How Charles River (CRL) is Placed Ahead of Q2 Earnings
by Zacks Equity Research
Growth across Microbial Solutions and Biologics Testing and CDMO businesses is likely to have contributed to Charles River's (CRL) Q2 revenues, offset by lower biopharmaceutical demand.
Charles River (CRL) Teams Up to Aid Stargardt's Disease Therapy
by Zacks Equity Research
Charles River (CRL) signs an agreement with AAVantgarde to produce GMP plasmid DNA for Stargardt's disease program.
Charles River (CRL) Could be an Apt Pick Right Now: Here's Why
by Zacks Equity Research
Investors are optimistic about Charles River (CRL) due to its business performance and strategic buyouts.
Charles River's (CRL) RMS Growth Aids Amid FX Headwind
by Zacks Equity Research
Charles River (CRL) broadens the scope of its products and services across the drug discovery and early-stage development continuum through focused acquisitions.
Charles River (CRL) Inks CDMO Deal With Gates Institutes
by Zacks Equity Research
Charles River (CRL) signs a lentiviral vector contract development and manufacturing organization agreement with Gates Institute to help develop chimeric antigen receptor (CAR) T-cell therapies.
Charles River (CRL) Advances in T-Cell Therapy With New Alliance
by Zacks Equity Research
Charles River (CRL) and Captain T Cell announced an agreement on plasmid DNA and retrovirus vector production program for the treatment of patients having solid tumor.
Charles River (CRL) Partners to Reduce Animal Research Usage
by Zacks Equity Research
Charles River (CRL) announces the development of non-clinical VCG with Sanofi to reduce the use of animals in research.
Charles River (CRL) Launches Viral Vector Tech Transfer Program
by Zacks Equity Research
Charles River's (CRL) new Fast Track and Modular frameworks facilitate product development continuity via accelerated process transfer to its viral vector Center of Excellence.
Reasons to Hold Charles River (CRL) in Your Portfolio Now
by Zacks Equity Research
Investors remain optimistic about Charles River (CRL), owing to its acquisitions, thriving DSA segment and financial stability.
Charles River (CRL) Banks on RMS Growth Amid Competition
by Zacks Equity Research
Charles River's (CRL) RMS arm sees lesser impact on demand than other life science sectors despite macroeconomic challenges in China.
Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JSMD
Don't Overlook Charles River (CRL) International Revenue Trends While Assessing the Stock
by Zacks Equity Research
Explore Charles River's (CRL) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Why Charles River Laboratories (CRL) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Charles River (CRL) Q1 Earnings & Revenues Beat, Fall Y/Y
by Zacks Equity Research
Charles River's (CRL) Manufacturing and RMS business segments report organic revenue growth.
Charles River (CRL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Charles River (CRL) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Sotera Health Company (SHC) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Sotera Health (SHC) delivered earnings and revenue surprises of -7.14% and 2.57%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?